Trade BioMarin Pharmaceutical Inc - BMRN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.12 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023457% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001235% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 71.99 |
| Open | 71.52 |
| 1-Year Change | -16.6% |
| Day's Range | 69.92 - 71.52 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 11, 2025 | 70.43 | -0.98 | -1.37% | 71.41 | 72.09 | 69.92 |
| Mar 10, 2025 | 71.99 | 0.08 | 0.11% | 71.91 | 72.87 | 71.44 |
| Mar 7, 2025 | 72.09 | 1.14 | 1.61% | 70.95 | 73.40 | 70.90 |
| Mar 6, 2025 | 71.18 | 1.07 | 1.53% | 70.11 | 71.49 | 70.11 |
| Mar 5, 2025 | 71.09 | 0.96 | 1.37% | 70.13 | 71.38 | 69.82 |
| Mar 4, 2025 | 70.62 | 0.52 | 0.74% | 70.10 | 71.47 | 69.75 |
| Mar 3, 2025 | 70.86 | 0.19 | 0.27% | 70.67 | 71.62 | 70.29 |
| Feb 28, 2025 | 71.11 | 2.34 | 3.40% | 68.77 | 71.14 | 68.58 |
| Feb 27, 2025 | 69.05 | 0.13 | 0.19% | 68.92 | 69.89 | 68.46 |
| Feb 26, 2025 | 68.73 | -2.25 | -3.17% | 70.98 | 70.98 | 68.28 |
| Feb 25, 2025 | 71.13 | 1.91 | 2.76% | 69.22 | 71.52 | 68.95 |
| Feb 24, 2025 | 68.95 | 0.80 | 1.17% | 68.15 | 70.02 | 67.36 |
| Feb 21, 2025 | 68.13 | -0.55 | -0.80% | 68.68 | 70.14 | 67.47 |
| Feb 20, 2025 | 68.38 | -1.32 | -1.89% | 69.70 | 70.04 | 66.66 |
| Feb 19, 2025 | 65.29 | 0.72 | 1.12% | 64.57 | 65.60 | 64.05 |
| Feb 18, 2025 | 64.61 | 0.31 | 0.48% | 64.30 | 65.78 | 64.05 |
| Feb 14, 2025 | 64.74 | 0.50 | 0.78% | 64.24 | 65.32 | 63.35 |
| Feb 13, 2025 | 64.31 | -0.67 | -1.03% | 64.98 | 65.69 | 63.96 |
| Feb 12, 2025 | 65.80 | 2.88 | 4.58% | 62.92 | 65.86 | 62.45 |
| Feb 11, 2025 | 63.48 | 0.78 | 1.24% | 62.70 | 63.54 | 62.31 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
BioMarin Company profile
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The Company’s portfolio consists of commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. The Company's commercial products include Aldurazyme (laronidase), Brineura (cerliponase alfa), Kuvan (sapropterin dihydrochloride), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Vimizim (elosulfase alpha) and Voxzogo (vosoritide). The Company's pipeline includes Valoctocogene Roxaparvovec for Severe Hemophilia A, Vosoritide for Achondroplasia, BMN 307 for Phenylketonuria (PKU) and BMN 331 for Hereditary Angioedema (HAE).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, BioMarin Pharmaceutical Inc. revenues decreased 1% to $1.85B. Net loss before extraordinary items totaled $68M vs. income of $4.6M. Revenues reflect Kuvan1 segment decrease of 38% to $285.8M, Naglazyme1 segment decrease of 3% to $380.4M, United States segment decrease of 28% to $657.7M, Latin America segment decrease of 7% to $191.2M.
Equity composition
Common Stock $.001 Par, 04/11, 250M auth., 110,909,591 issd. Insiders own 0.26%. IPO 7/23/99, 4.5M shs. $13 by U.S. Bancorp Piper Jaffray. PO 12/01, 8,050,000 shs. @ $12 by UBS Warburg. 5/01, private placement 4,763,712 shares @ $9.45. PO 2/03, 7.5M shs @ $10 by UBS Warburg. PO 3/06 10,350,000 shs. @ $13/sh.
| Industry: | Biopharmaceuticals |
105 Digital Dr
NOVATO
CALIFORNIA 94949
US
News
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com